Roivant's Priovant to file sNDA for brepocitinib for NIU in 1H 2027.
Sentimentbullish 75
Bullish · 75 of 100
Impact60
medium · sector-wide
Confidence70%
moderate confidence · single wire
Eventdeveloping
v1 · alerted to followers
FREE ACCOUNT · NO CARD
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
WHY IT MATTERS••••••••••Market transmission and exposed assetsBULL / BEAR CASE•••• / ••••Competing evidence, edited togetherNEWS ON PRICE••.•% reactionConfirmation versus SPY and sectorWHAT TO WATCH•• catalystsThe facts that can change the read
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
Roivant's Priovant to file sNDA for brepocitinib for NIU in 1H 2027bullish 75 · impact 60 · this page
Roivant Sciences: 62% of Brepocitinib patients achieved steroid-free quiescence at week 48 vs 20% placebo in pooled CLARITY databullish 85 · impact 75
Roivant Sciences: brepocitinib shows median time to treatment failure >48 weeks vs 12 weeks placebo in two studiesbullish 80 · impact 60
Roivant Sciences reports positive results for Brepocitinib in CLARITY-1 and CLARITY-2 trialsbullish 80 · impact 60
Roivant Sciences: CLARITY-1 and CLARITY-2 are identical Phase 3 trials in NIU programneutral 50 · impact 20 · first wire
Where this story sitsringed dot is this story
bullishneutralbearishlabel = ticker sentiment·impact · dot size follows impact · click a dot to open the story
Every story, completefree account
A free account opens the reasons behind every story, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone, plus 3 complete ticker and report views a day. BORSA Plus removes the daily limit and adds alerts on your names.
BORSA uses AI-assisted classification and synthesis with deterministic event controls. Market sentiment is informational and is not individualized investment advice.
